Compare Citius Pharmaceuticals Inc (CTXR) vs Figure Technology Solutions Inc. Class A Common Stock (FIGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Figure Technology Solutions Inc. Class A Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Figure Technology Solutions Inc. Class A Common Stock trades at $28.54 (market cap $6.19B). The key difference: Figure Technology Solutions Inc. Class A Common Stock is far larger — about 454.5× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is more actively traded (132,438 versus 4,762,342). Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Figure Technology Solutions Inc. Class A Common Stock for 1 Days on average.
| CTXR | FIGR | |
|---|---|---|
Market Cap | $13.62M | $6.19B |
Volume | 132,438 | 4,762,342 |
Sector | Health | Financials |
52-Week High | $1.82 | $73.91 |
52-Week Low | $0.48 | $24.91 |
Typical Hold Time | 17 Days | 1 Days |
Enterprise Value | $3.79M | $6.23B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Figure Technology Solutions Inc. Class A Common Stock
Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.
Read more on FIGR →
